Skip to content

A Multicenter observational study on the effectiveness and tolerability of Hexilak Acne scar serum used with device-based procedures for acne scar treatment (Adjuvant Real-World Evidence Study).

Prospective, observational multicenter Study for effectiveness and tolerability of Hexilak acne scar serum when used along with device-based procedures (Adjuvant Study for Acne Scar Treatment- Understanding Real-world Evidence) - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/12/098453
Enrollment
500
Registered
2025-12-04
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Hexilak acne scar serum: Once or Twice daily as directed by Investigator for 90 days

Sponsors

Menarini India Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Healthy participants of either gender from 18-45 years of age after assessing medical history, physical examination and clinical judgment of the investigator. 2) Participants are diagnosed clinically with acne scars with or without hyperpigmentation. 3) Participants who have not undergone any scar treatment in the past 6 months. 4) Willing to refrain from use of all other topical medications as per Investigator discretion, that will significantly affect the study results. the use of other cosmetic products on face during the course of the study. 5) Cooperating, informed of the need and duration of the examinations, and ready to comply with protocol procedures. 6) Having signed a Consent Form, after being informed orally and in writing of all information concerning the study procedures and study objectives.

Exclusion criteria

Exclusion criteria: 1) Pregnant women or lactating women. 2) Participants with a history of allergic dermatitis or contact allergy to cosmetics, with known sensitivity to any of the ingredients in the study product. 3) Presence of any other skin conditions, diseases, or medical conditions in the investigators opinion might require concurrent therapy and interfere with the evaluation of the study medication or compromise patients safety.

Design outcomes

Primary

MeasureTime frame
Evaluate percentage of subjects showing improvement in acne scars on Physician Global Aesthetic Improvement ScaleTimepoint: Day 90

Secondary

MeasureTime frame
Percentage of subjects showing improvement in acne scars on Physician Global Aesthetic Improvement Scale.Timepoint: Day 30;Mean change in Physician Global Aesthetic Improvement Scale at all follow up of treatment visits.Timepoint: Day 30, Day 60, and Day 90;Percentage of subjects showing improvement in acne scars on Subject Global Aesthetic Improvement Scale at all follow up of treatment visits.Timepoint: Day 30, Day 60, and Day 90;Mean change in Subject Global Aesthetic Improvement Scale at all follow up of treatment visits.Timepoint: Day 30, Day 60, and Day 90;Mean change in Post Acne Hyperpigmentation Index as compared to baseline.Timepoint: Day 1, Day 30, Day 60, and Day 90;Percentage of subjects on Subject satisfaction score.Timepoint: Day 30, Day 60, and Day 90

Countries

India

Contacts

Public ContactDr TD Rajan

Dr. T. D. Rajans Clinic

skinbeautydoc@gmail.com9821024437

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026